*Note concerning Special Order chemicals: these are made to order in 1 to 8 weeks.
The minimum order size is 1, 5, or 20 grams. Prices are listed in the catalog for available quantities only.
Catalog Number |
CASRN |
Structure |
Availability |
FW |
Chemical Name |
Purity |
|
| FS000766 |
850349-22-3 |
 |
In Stock |
214 |
2-Azetidin-1-yl-5-bromo-pyrimidine
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| 195 |
295 |
495 |
995 |
2995 |
5995 |
|
| FS011447 |
191602-70-7 |
 |
In Stock |
264 |
2-Bromo-1-(2-fluoro-ethoxy)-4-nitro-benzene
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| 95 |
295 |
495 |
995 |
2995 |
4995 |
|
| FS000286 |
148038-83-9 |
 |
In Stock |
214 |
6-Bromo-1H-imidazo[4,5-b]pyridin-2(3H)-one
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| 75 |
95 |
195 |
495 |
1995 |
2995 |
|
| FS000661 |
85508-99-2 |
 |
In Stock |
193 |
4-Bromo-3-methyl-isothiazol-5-ylamine
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| 75 |
95 |
195 |
495 |
1995 |
3995 |
|
| FS000660 |
20493-60-1 |
 |
In Stock |
178 |
5-Bromo-3-methyl-isothiazole
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
1250 |
4250 |
|
|
Catalog Number |
CASRN |
Structure |
Availability |
FW |
Chemical Name |
Purity |
|
| FS000683 |
6188-23-4 |
 |
In Stock |
197 |
6-Bromo-imidazo[1,2-a]pyridine
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
75 |
95 |
295 |
1395 |
3495 |
|
| FS000684 |
850349-02-9 |
 |
In Stock |
197 |
8-Bromo-imidazo[1,2-a]pyridine
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| 75 |
145 |
245 |
495 |
1950 |
3450 |
|
| FS001231 |
850348-58-2 |
 |
In Stock |
227 |
2-(3-Bromo-phenyl)-2-methyl-oxetane
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
95 |
125 |
245 |
1150 |
2950 |
|
| FS000726 |
39891-08-2 |
 |
In Stock |
197 |
(5-Bromo-pyridin-3-yl)-acetonitrile
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| 75 |
95 |
195 |
395 |
1695 |
4495 |
|
| FS000622 |
52333-42-3 |
 |
In Stock |
210 |
7-Bromo-pyrido[2,3-b]pyrazine
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| 75 |
95 |
195 |
495 |
1950 |
3450 |
|
| FS011399 |
380605-23-2 |
 |
In Stock |
175 |
3-Cyclopropyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| 95 |
195 |
395 |
995 |
2995 |
6995 |
|
Catalog Number |
CASRN |
Structure |
Availability |
FW |
Chemical Name |
Purity |
|
| FS001685 |
17385-20-5 |
 |
In Stock |
212 |
1,4-Dithia-8-aza-spiro[4.5]decane hydrochloride
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| 75 |
95 |
195 |
650 |
1900 |
3350 |
|
| FS011339 |
137830-77-4 |
 |
In Stock |
150 |
2-Methyl-[1,2,6]thiadiazinane 1,1-dioxide
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| 75 |
145 |
295 |
495 |
1995 |
3495 |
|
| FS000658 |
693-92-5 |
 |
In Stock |
99 |
3-methylisothiazole
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
995 |
3995 |
|
|
| FS011416 |
6635-88-7 |
 |
In Stock |
134 |
(1-Oxy-pyridin-3-yl)-acetonitrile
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| 75 |
95 |
195 |
295 |
1350 |
3950 |
|
| FS001243 |
36170-23-7 |
 |
Special Order* |
173 |
4-Aza-tricyclo[5.2.1.0 2,6 ]decane hydrochloride
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
1450 |
2950 |
4950 |
|
| FS000771 |
273-77-8 |
 |
Special Order* |
136 |
Benzo[1,2,3]thiadiazole
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
1350 |
2950 |
4950 |
|
Catalog Number |
CASRN |
Structure |
Availability |
FW |
Chemical Name |
Purity |
|
| FS000284 |
155629-94-0 |
 |
Special Order* |
224 |
7-Bromo-2-methylpyrido[2,3-b]pyrazine
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
1150 |
2950 |
4950 |
|
| FS000680 |
850349-00-7 |
 |
Special Order* |
212 |
4-Bromo-5,6,7,8-tetrahydro-isoquinoline
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
995 |
2995 |
5995 |
|
| FS011338 |
6008-52-2 |
 |
Special order* |
134 |
[1,3]Dithiepane
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
950 |
2450 |
3950 |
|
| FS011397 |
17768-36-4 |
 |
Special Order* |
210 |
(3-Hydroxy-adamantan-1-yl)-acetic acid
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
950 |
2450 |
3950 |
|
| FS000667 |
|
 |
Special Order* |
119 |
3H-Imidazo[4,5-c]pyridine
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
1995 |
3995 |
6995 |
|
| FS000664 |
68175-07-5 |
 |
Special Order* |
133 |
2-Methyl-3H-imidazo[4,5-b]pyridine
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
995 |
3495 |
5995 |
|
Catalog Number |
CASRN |
Structure |
Availability |
FW |
Chemical Name |
Purity |
|
| FS000668 |
63604-59-1 |
 |
Special Order* |
133 |
2-Methyl-3H-imidazo[4,5-c]pyridine
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
1995 |
3995 |
|
|
| FS000666 |
71109-34-7 |
 |
Special Order* |
150 |
3-Methyl-isothiazolo[5,4-b]pyridine
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
|
|
3900 |
|
| FS001258 |
185546-54-7 |
 |
Special Order* |
156 |
(S,S)-Octahydro-benzoimidazole-2-thione
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
1350 |
2950 |
4950 |
|
| FS001259 |
139237-77-7 |
 |
Special Order* |
156 |
(R,R)-Octahydro-benzoimidazole-2-thione
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
1350 |
2950 |
4950 |
|
| FS011340 |
63010-19-5 |
 |
Special Order* |
150 |
[1,2,7]Thiadiazepane 1,1-dioxide
|
>95% |
| Price in US$ |
10 mg |
100 mg |
250 mg |
1g |
5g |
20g |
| |
|
|
1350 |
2950 |
4950 |
|
Recently, a set of rules has been developed to help identify small molecules suited for the fragment-based lead discovery. This novel approach to drug discovery involves screening libraries of low-molecular weight fragments for their ability to interact with a macromolecular target through protein x-ray crystallography or NMR. Congreve, Carr, Murray and Jhoti determined that small molecules that obey the "Rule of Three" are most suited to this approach: FW < 300, hydrogen bond donors <=3, hydrogen bond acceptors <=3, ClogP <=3. Focus Synthesis offers RubyRO3 building blocks, a set of over 150 building synthons and precursors that meet the basic Rule of Three criteria. More than 80% of these are predicted to be stable in physiological buffers, and could be used directly as screening compounds particularly suited for fragment-based lead discovery. 100% of the "Rule of Three" products are ideal lead candidates, particularly well suited as precursors for lead-like and drug-like molecules to keep drug discovery pipelines full of high quality drug candidates. Purchase RubyRO3 chemicals to accelerate your fragment-based screening progam.